AKBA logo

AKBA
Akebia Therapeutics Inc.

20,871
Mkt Cap
$375.03M
Volume
2.05M
52W High
$4.08
52W Low
$1.14
PE Ratio
-77.78
AKBA Fundamentals
Price
$1.40
Prev Close
$1.41
Open
$1.41
50D MA
$1.35
Beta
1.26
Avg. Volume
2.82M
EPS (Annual)
-$0.0208
P/B
11.40
Rev/Employee
$1.22M
$443.78
Loading...
Loading...
News
all
press releases
Akebia Therapeutics (NASDAQ:AKBA) Rating Increased to Hold at Zacks Research
Zacks Research upgraded Akebia Therapeutics from a "strong sell" rating to a "hold" rating in a research note on Tuesday...
MarketBeat·3d ago
News Placeholder
More News
News Placeholder
BTIG Research Reaffirms "Buy" Rating for Akebia Therapeutics (NASDAQ:AKBA)
BTIG Research reiterated a "buy" rating and issued a $4.00 target price on shares of Akebia Therapeutics in a research note on Tuesday...
MarketBeat·5d ago
News Placeholder
Akebia Therapeutics R&D Day: Vafseo Growth Plan, Praliciguat Phase 2, New Kidney Pipeline Targets
Akebia Therapeutics (NASDAQ:AKBA) used its R&D Day presentation to outline a strategy centered on expanding its commercial anemia franchise while advancing three kidney disease pipeline programs...
MarketBeat·10d ago
News Placeholder
Guardian Pharmacy (GRDN) Soars 9.1%: Is Further Upside Left in the Stock?
Guardian Pharmacy (GRDN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Zacks·12d ago
News Placeholder
Nordea Investment Management AB Takes Position in Akebia Therapeutics, Inc. $AKBA
Nordea Investment Management AB acquired a new position in shares of Akebia Therapeutics, Inc. (NASDAQ:AKBA - Free Report) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 752,106 shares of the biopharmaceutical comp...
MarketBeat·14d ago
News Placeholder
Is the Options Market Predicting a Spike in Akebia Therapeutics Stock?
Investors need to pay close attention to AKBA stock based on the movements in the options market lately.
Zacks·26d ago
News Placeholder
Akebia Therapeutics Details Vafseo Commercial Push, TIW Dosing Plans and Kidney Pipeline at Leerink Conference
Akebia Therapeutics (NASDAQ:AKBA) executives outlined the company's near- and mid-term priorities at the Leerink Partners Global Healthcare Conference, emphasizing the commercialization of its anemia...
MarketBeat·1mo ago
News Placeholder
Akebia Therapeutics (NASDAQ:AKBA) CEO John Butler Purchases 69,270 Shares
Akebia Therapeutics, Inc. (NASDAQ:AKBA - Get Free Report) CEO John Butler purchased 69,270 shares of the business's stock in a transaction on Wednesday, March 4th. The stock was acquired at an...
MarketBeat·1mo ago
News Placeholder
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Short Interest Update
Akebia Therapeutics, Inc. (NASDAQ:AKBA - Get Free Report) was the target of a large decline in short interest in February. As of February 13th, there was short interest totaling 31,207,330 shares, a...
MarketBeat·1mo ago
News Placeholder
Citigroup Inc. Has $5.23 Million Position in Akebia Therapeutics, Inc. $AKBA
Citigroup Inc. boosted its stake in Akebia Therapeutics, Inc. (NASDAQ:AKBA - Free Report) by 1,324.7% in the third quarter, according to its most recent Form 13F filing with the Securities and...
MarketBeat·1mo ago
<
1
2
...
>

Latest AKBA News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.